Press Release

Xerostomia Therapeutics Market to Grow with a CAGR of 3.78% through 2028

Increase in the incidence of chronic diseases and increase in the aging population is expected to drive the Global Xerostomia Therapeutics Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Xerostomia Therapeutics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Xerostomia Therapeutics Market stood at USD 1.98 billion in 2022 and is anticipated to grow with a CAGR of 3.78% in the forecast period, 2024-2028. The awareness among individuals regarding Xerostomia Therapeutics has led to favorable market conditions for the global Xerostomia Therapeutics market. Several factors contribute to the growth of various Xerostomia Therapeutics products.

The global population is aging, with a substantial increase in the elderly demographic. Xerostomia is more prevalent among older individuals due to the natural aging process, as well as the use of medications commonly associated with reduced saliva production. As the elderly population grows, so does the demand for xerostomia therapeutics. Pharmaceutical companies and healthcare providers are focusing on developing and offering effective treatments for this age group, which is driving market growth.

                                                                                             

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Xerostomia Therapeutics Market

 

Many medications, including antihypertensives, antidepressants, antihistamines, and anticholinergics, have dry mouth as a common side effect. As the prevalence of chronic diseases rises, so does the consumption of these medications. This, in turn, leads to a higher incidence of xerostomia. The need for effective therapeutics to manage this condition is growing, as patients seek relief from the discomfort and potential oral health issues associated with dry mouth.

In October 2023, CL is committed to sustainability and is taking steps to reduce its environmental impact. The company has set a goal of becoming carbon neutral by 2040. In addition, CL is working to reduce its use of plastic and to source more sustainable materials for its products.

Chronic illnesses, such as diabetes and Sjögren's syndrome, are often associated with xerostomia. With the increasing prevalence of these diseases worldwide, the number of individuals suffering from dry mouth is also on the rise. Consequently, there is a growing demand for xerostomia therapeutics, both pharmaceutical and non-pharmaceutical, to alleviate the symptoms and improve the quality of life for these patients.

In today's fast-paced world, Dry mouth can be distracting and uncomfortable, making it difficult to concentrate on tasks. Xerostomia therapeutics help individuals regain their focus by alleviating dry mouth symptoms, allowing them to work, study, or perform tasks more effectively. Effective communication is vital in a fast-paced world, whether in the workplace, social settings, or during important meetings. Xerostomia therapeutics, such as lozenges or saliva substitutes, can reduce the discomfort associated with speaking, making it easier for individuals to express themselves clearly and confidently. Sustained Energy Levels: In a busy environment, maintaining energy levels is crucial. Dry mouth can hinder the consumption of water and food, potentially leading to dehydration and decreased energy. Xerostomia therapeutics can improve hydration and promote better eating habits, thus contributing to sustained energy throughout the day. Enhanced Nutrition: Malnutrition and dietary deficiencies can result from persistent dry mouth, as individuals may struggle to eat certain foods. Xerostomia therapeutics help improve nutrition by facilitating the consumption of a wider variety of foods, supporting overall health and vitality. Less Time Lost to Discomfort: Dry mouth can lead to frequent breaks to drink water or address discomfort. Xerostomia therapeutics reduce the need for these interruptions, allowing individuals to stay on task and maintain productivity levels. Enhanced Workplace Performance: In professional settings, improved oral comfort means employees can focus on their work without the distraction of dry mouth symptoms. This contributes to enhanced workplace performance and efficiency.

Advancements in medical research and technology have led to the development of innovative treatment options for xerostomia. These include prescription medications, saliva substitutes, and medical devices like salivary stimulants. These new products and therapies offer more effective and targeted solutions for managing dry mouth, which can significantly improve patient outcomes.

In recent times, The use of various medications has risen over time, contributing to a growing incidence of medication-induced dry mouth. Xerostomia therapeutics help individuals manage this common side effect, ensuring that they can continue necessary treatments without experiencing excessive discomfort. Recent demographic shifts indicate a substantial increase in the aging population worldwide. Age-related factors often lead to xerostomia. Xerostomia therapeutics are invaluable for elderly individuals, as they help maintain oral health and comfort, improving the quality of life for this demographic. The prevalence of chronic diseases such as diabetes, Sjogren's syndrome, and cancer, all of which are associated with xerostomia, is on the rise. Xerostomia therapeutics play a critical role in managing dry mouth symptoms in patients with these conditions. However, Limited Awareness and Diagnosis may hinder market growth. Moreover, challenges related to Fragmented Market and Treatment Approaches and Regulatory and Reimbursement Challenges may pose obstacles to the Xerostomia Therapeutics market in the near future.

The Global Xerostomia Therapeutics Market is segmented into type, product, regional distribution, and company

Based on its type, the OTC xerostomia therapeutics, which include saliva substitutes, oral moisturizers, and lozenges, can be purchased without a prescription. This ease of access means that individuals experiencing dry mouth symptoms can obtain relief products conveniently from local pharmacies, drugstores, or even online retailers without the need for a healthcare provider's authorization. OTC products are readily available on store shelves and online marketplaces. Consumers can purchase them on the spot or have them delivered to their homes, offering immediate relief to those suffering from the discomfort of xerostomia. In contrast, prescription-based therapeutics may involve a delay in obtaining the treatment. OTC products empower consumers to choose the specific xerostomia therapeutics that best suit their needs. This freedom of choice allows individuals to select products based on factors like taste, texture, ingredients, and personal preferences, enhancing their overall experience and satisfaction. Many individuals prefer to take control of their healthcare, especially for non-severe conditions like xerostomia. OTC products enable self-care, giving individuals the autonomy to manage their symptoms without the need for repeated visits to healthcare providers. This self-care trend aligns with the broader movement toward preventive health and wellness.

Based on region, North America segment is expected to grow during the forecast period.  North America boasts advanced healthcare infrastructure with well-established healthcare systems, making it easier for patients to access specialized treatments and for pharmaceutical companies to introduce new xerostomia therapeutics. North America has a high prevalence of chronic diseases like diabetes and autoimmune disorders, which are often associated with xerostomia. This increases the demand for xerostomia therapeutics in the region. The use of medications that can cause dry mouth is also widespread in North America. This contributes to the high incidence of xerostomia and drives the demand for treatments. The region is home to many major pharmaceutical companies known for their commitment to research and development. These companies focus on innovating xerostomia therapeutics, introducing new and improved treatment options. Health insurance coverage in North America is relatively common, making xerostomia therapeutics more accessible to a larger portion of the population. Patients are more likely to seek and afford treatment, contributing to the market's dominance.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Xerostomia Therapeutics players during the forecast period. Factors such as Asia-Pacific region are experiencing a growing middle class with increased disposable income. This demographic shift leads to higher healthcare expenditure and greater willingness to seek treatment for health conditions, including xerostomia. The Asia-Pacific region has a significantly larger population compared to North America. With an aging population and an increased incidence of chronic diseases, there is a substantial pool of potential xerostomia patients, which fuels market growth. The region is witnessing increased healthcare awareness, and patients are becoming more informed about their health conditions and available treatment options. Infrastructure improvements and greater access to healthcare services, including dental care, are contributing to the diagnosis and management of xerostomia in the region.

Major companies operating in Global Xerostomia Therapeutics Market are:

  • GlaxoSmithKline plc
  • Church & Dwight Co., Inc.
  • Colgate-Palmolive Company
  • Hikma Pharmaceuticals PLC
  • Pendopharm
  • Sun Pharmaceuticals Industries Ltd
  • Lupin Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Parnell Pharmaceuticals, Inc.
  • Acacia Pharma

 

Download Free Sample Report

Customers can also request for 10% free customization on this report

 

“The Technological Advancements and Product Innovation and increasing Awareness and Diagnosis are key drivers of the Xerostomia Therapeutics market. In recent years, the growing emphasis on patient well-being and the demand for personalized healthcare solutions drive the adoption of xerostomia therapeutics that improve patients' quality of life. Moreover, the growing consumer emphasis on preventative healthcare products has enhanced production and marketing efforts. To meet the demands of the market, manufacturers are increasingly incorporating cutting-edge technologies with high production efficiency. Rising consumer acceptance and continuous product innovation will further ensure the growth of the Xerostomia Therapeutics market in the coming years.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Xerostomia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (OTC, Prescription), By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Xerostomia Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Xerostomia Therapeutics Market.

 

Contact Us-

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

M: +13322586602

Email: [email protected]

Website: www.techsciresearch.com

Relevant Reports

Relevant News